Website
News25/Ratings4
News · 26 weeks32-87%
2025-10-262026-04-19
Mix1790d
- Insider8(47%)
- SEC Filings5(29%)
- Other3(18%)
- Earnings1(6%)
Latest news
25 items- SECPepGen Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - PepGen Inc. (0001835597) (Filer)
- PRPepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data– PGN-EDODM1 was generally well-tolerated with all adverse events mild or moderate and no serious adverse events reported – – Mean splicing correction of 7.3% observed with PGN-EDODM1 (n=6) versus 6.8% with placebo (n=2); Excluding one outlier patient, treatment group demonstrated mean splicing correction of 22.9% (n=5) – – Promising trends observed in vHOT in the PGN-EDODM1 treated group – – Company on track to report clinical data from 10 mg/kg multiple dose cohort in 2H 2026 with sufficient cash expected to fund operations into 2H 2027– – Conference call scheduled today at 4:30 p.m. ET – PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next genera
- SECSEC Form SCHEDULE 13G filed by PepGen Inc.SCHEDULE 13G - PepGen Inc. (0001835597) (Subject)
- INSIDEREVP, Head of R&D Streck Paul sold $11,709 worth of shares (1,879 units at $6.23), decreasing direct ownership by 2% to 76,226 units (SEC Form 4)4 - PepGen Inc. (0001835597) (Issuer)
- INSIDERChief Financial Officer Donnelly Noel sold $12,988 worth of shares (2,084 units at $6.23), decreasing direct ownership by 2% to 111,603 units (SEC Form 4)4 - PepGen Inc. (0001835597) (Issuer)
- INSIDERPresident and CEO Mcarthur James G sold $32,876 worth of shares (5,275 units at $6.23), decreasing direct ownership by 2% to 296,326 units (SEC Form 4)4 - PepGen Inc. (0001835597) (Issuer)
- SECPepGen Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - PepGen Inc. (0001835597) (Filer)
- SECSEC Form S-8 filed by PepGen Inc.S-8 - PepGen Inc. (0001835597) (Filer)
- SECSEC Form 10-K filed by PepGen Inc.10-K - PepGen Inc. (0001835597) (Filer)
- SECPepGen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - PepGen Inc. (0001835597) (Filer)
- PRPepGen Announces Regulatory Updates on FREEDOM2- U.S. FDA places FREEDOM2 trial on partial clinical hold related to preclinical pharmacology and toxicology - - Received regulatory clearance to initiate FREEDOM2 in South Korea, Australia, and New Zealand and dosing of the 10 mg/kg cohort continues in the UK and Canada - - PepGen reiterates guidance for reporting data from the FREEDOM2 5 mg/kg cohort in Q1 2026 and from the 10 mg/kg cohort in 2H 2026 - PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies to treat severe neuromuscular and neurological diseases, today announced regulatory updates related to the FREEDOM2 trial. The U.S. Food and Drug Administrati
- PRPepGen to Participate in the Leerink Global Healthcare ConferencePepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that James McArthur, PhD, President and CEO of PepGen, will participate in a fireside chat at the Leerink Global Healthcare Conference on Tuesday, March 10, 2026 at 3:00 p.m. ET in Miami, Florida. A webcast of the event will be available on the "Events & Presentations" page within the Investors section of the PepGen website at https://investors.pepgen.com/. A replay of the webcast will be available on the PepGen website for 90 days following the presentatio
- INSIDERChief Business & Legal Officer Vittiglio Joseph was granted 30,717 shares, increasing direct ownership by 88% to 65,717 units (SEC Form 4)4 - PepGen Inc. (0001835597) (Issuer)
- INSIDERChief Technical Officer Kasraian Kasra was granted 34,557 shares, increasing direct ownership by 206% to 51,307 units (SEC Form 4)4 - PepGen Inc. (0001835597) (Issuer)
- INSIDEREVP, Head of R&D Streck Paul was granted 50,300 shares, increasing direct ownership by 181% to 78,105 units (SEC Form 4)4 - PepGen Inc. (0001835597) (Issuer)
- INSIDERChief Financial Officer Donnelly Noel was granted 76,793 shares, increasing direct ownership by 208% to 113,687 units (SEC Form 4)4 - PepGen Inc. (0001835597) (Issuer)
- INSIDERPresident and CEO Mcarthur James G was granted 187,688 shares, increasing direct ownership by 165% to 301,601 units (SEC Form 4)4 - PepGen Inc. (0001835597) (Issuer)
- INSIDERSEC Form 4 filed by EVP, Head of R&D Streck Paul4 - PepGen Inc. (0001835597) (Issuer)
- INSIDERSEC Form 4 filed by President and CEO Mcarthur James G4 - PepGen Inc. (0001835597) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Donnelly Noel4 - PepGen Inc. (0001835597) (Issuer)
- INSIDERChief Business & Legal Officer Vittiglio Joseph was granted 35,000 shares (SEC Form 4)4 - PepGen Inc. (0001835597) (Issuer)
- INSIDERSEC Form 3 filed by new insider Vittiglio Joseph3 - PepGen Inc. (0001835597) (Issuer)
- PRPepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Business and Legal OfficerPepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced it awarded an inducement grant under PepGen's 2024 Inducement Plan as a material inducement to employment to its newly appointed Chief Business and Legal Officer, Joseph Vittiglio. On December 8, 2025, Mr. Vittiglio received a non-qualified stock option grant to purchase 160,000 shares of PepGen's common stock, par value $0.0001 per share, with an exercise price of $5.59 per share, the closing price of PepGen's common stock as reported by The Nasdaq Global S
- SECPepGen Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - PepGen Inc. (0001835597) (Filer)
- PRPepGen Appoints Joseph Vittiglio, Esq., as Chief Business and Legal OfficerPepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Joseph Vittiglio, Esq., as Chief Business and Legal Officer. Mr. Vittiglio brings more than two decades of executive leadership experience across legal, compliance, corporate development, and corporate governance within public biotechnology companies. "Joe is a deeply experienced legal and business leader with a proven track record guiding companies through complex transactions, regulatory milestones, financings, product launches, and stra